ROS 234 dioxalate
Potent H3 antagonist (pKB at guinea-pig ileum H3-receptor = 9.46). Limited blood brain barrier permeability (ED50 = 19.12 mg/kg i.p.).
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 421.37. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.37 mL||11.87 mL||23.73 mL|
|5 mM||0.47 mL||2.37 mL||4.75 mL|
|10 mM||0.24 mL||1.19 mL||2.37 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Ballabeni et al (2002) CNS access of selected H3-antagonists: ex vivo binding study in rats. Inflamm.Res. 51 S55 PMID: 12013409
If you know of a relevant reference for ROS 234 dioxalate, please let us know.
View Related Products by Product Action
Keywords: ROS 234 dioxalate, supplier, Potent, H3, antagonists, Receptors, Histamine, histaminergic, ROS234, dioxalate, Histamine, H3, Receptors, Tocris Bioscience
Citations for ROS 234 dioxalate
Citations are publications that use Tocris products.
Currently there are no citations for ROS 234 dioxalate. Do you know of a great paper that uses ROS 234 dioxalate from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.